2898 Stock Overview
A biopharmaceutical company, engages in the discovery, development, and commercialization of biologics that regulate immune microenvironment by modulating the innate and adaptive immune systems. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Sunho Biologics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$4.15 |
| 52 Week High | HK$15.42 |
| 52 Week Low | HK$4.11 |
| Beta | 0 |
| 1 Month Change | -17.17% |
| 3 Month Change | -32.63% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -71.42% |
Recent News & Updates
Shareholder Returns
| 2898 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -5.3% | -1.8% | 2.5% |
| 1Y | n/a | -4.7% | 20.8% |
Return vs Industry: Insufficient data to determine how 2898 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 2898 performed against the Hong Kong Market.
Price Volatility
| 2898 volatility | |
|---|---|
| 2898 Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.8% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 2898 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2898's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 124 | Liusong Yin | www.sunho-bio.com.cn |
Sunho Biologics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics that regulate immune microenvironment by modulating the innate and adaptive immune systems. It offers IAH0968, an antibody-dependent cell mediated cytotoxicity enhanced monoclonal antibody, which is in the Phase II clinical trials for biliary tract carcinoma and colorectal cancer (CRC). The company also provides IAP0971 and IAE0972 immunocytokines, which have completed Phase I clinical trials for advanced solid tumors, including non-small cell lung cancer and CRC.
Sunho Biologics, Inc. Fundamentals Summary
| 2898 fundamental statistics | |
|---|---|
| Market cap | HK$625.27m |
| Earnings (TTM) | -HK$114.75m |
| Revenue (TTM) | HK$12.38m |
50.5x
P/S Ratio-5.4x
P/E RatioIs 2898 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2898 income statement (TTM) | |
|---|---|
| Revenue | CN¥11.57m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥11.57m |
| Other Expenses | CN¥118.86m |
| Earnings | -CN¥107.29m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | 100.00% |
| Net Profit Margin | -927.14% |
| Debt/Equity Ratio | 4.2% |
How did 2898 perform over the long term?
See historical performance and comparison